Search clinical trials for: Yttrium-90 radioembolization

Total 1205 results

National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
McGill University
McGill University Health Centre/Research Institute of the McGill University...

Unknown

Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL (SPINOZA)

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Charite University, Berlin, Germany

Completed

Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults

Older Adults (50-90 Years)

Germany
Sirtex Medical

Withdrawn

FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma (FAST)

Liver Metastases | Colorectal Carcinoma

United States
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Recruiting

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
ABK Biomedical

Recruiting

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
Chandrikha Chandrasekharan
AstraZeneca; Biocompatibles UK Ltd

Suspended

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Rectal Cancer | Colon Cancer | Colorectal Cancer Metastatic | Liver Metastases | Colo-rectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Liver Metastasis Colon Cancer

United States
National and Kapodistrian University of Athens

Unknown

Laser Therapy in Managing Vaginal Prolapse

Cystocele | Vaginal Vault Prolapse | Rectocele | Enterocele

Greece
Novartis Pharmaceuticals

Completed

Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer

Breast Cancer | Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States
Dartmouth-Hitchcock Medical Center
Spectrum Pharmaceuticals, Inc; Cephalon

Completed

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

Lymphoma, Follicular

United States
Case Comprehensive Cancer Center

Completed

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

Hepatic Malignancies

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Northwestern University

Completed

Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

Metastatic Cancer | Liver Cancer

United States
University of Miami

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
Emory University

Terminated

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

Pancreatic Neoplasms | Cholangiocarcinoma

United States
Hallym University Kangnam Sacred Heart Hospital

Recruiting

Combined Intense Pulsed Light (IPL) With Fractional Erbium:YAG Laser Ablation in Scar Prevention

Intense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar Prevention

Korea, Republic of
ABK Biomedical

Completed

Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC

Metastatic Colorectal Cancer | Liver Cancer | Hepatocellular Carcinoma Non-resectable

New Zealand
SCRI Development Innovations, LLC
Ipsen

Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Gastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid Tumors

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Sandeep Laroia
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Terminated

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Neuroendocrine Tumors

United States
David Minor, MD
University of Chicago; Jefferson Medical College of Thomas Jefferson University and other collaborators

Active, not recruiting

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Uveal Melanoma | Hepatic Metastases

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Withdrawn

Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma
National Cancer Institute (NCI)

Terminated

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Testicular Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse... and other conditions

United States
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
University of Nebraska
Biogen

Completed

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

Lymphoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

Head and Neck Cancer | Metastatic Cancer | Pheochromocytoma | Islet Cell Tumor

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center

Withdrawn

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Advanced Cancers
University of Southampton

Terminated

Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

Lymphoma

United Kingdom
University of Arizona
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL (ESHAP)

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
Technical University of Munich

Unknown

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany
Zhongda Hospital

Recruiting

Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM

Colorectal Cancer Metastatic

China
National Cancer Institute (NCI)

Completed

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

Lymphoma, T-Cell, Cutaneous | Leukemia, T-Cell

United States
Riphah International University

Completed

Functional DN for Shortened HS Muscle

Hamstring Contractures

Pakistan
Northwestern University
National Cancer Institute (NCI)

Completed

Quality of Life in Patients Undergoing Embolization Using Yttrium Y 90 Glass Microspheres for Primary or Metastatic Liver Cancer

Metastatic Cancer | Liver Cancer

United States
Charite University, Berlin, Germany

Recruiting

Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis (SirTac)

Uveal Melanoma

Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
Centre Antoine Lacassagne

Completed

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Lymphoma

France
Universiti Putra Malaysia

Recruiting

Effect of Cardiac Rehabilitation on Health Status, Emotional Outcomes, and 90-day Readmission Rate Among Cardiac Surgery Patients

Depression | Anxiety | Health Status | 90-day Readmission

Jordan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditions

United States
Boston Scientific Corporation
Biocompatibles UK Ltd

Terminated

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein (YES-P)

Hepatocellular Carcinoma

Spain, United Kingdom, United States, Belgium, France, Italy
Singapore Clinical Research Institute
National Medical Research Council (NMRC), Singapore; Sirtex Medical; Bayer Healthcare...

Completed

Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Singapore, Korea, Republic of, Malaysia, Myanmar
Great Ormond Street Hospital for Children NHS Foundation...

Recruiting

90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (RITII)

Leukemia

United Kingdom

Search clinical trials for: Yttrium-90 radioembolization

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations